<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28632">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733991</url>
  </required_header>
  <id_info>
    <org_study_id>CEP311</org_study_id>
    <nct_id>NCT02733991</nct_id>
  </id_info>
  <brief_title>Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes</brief_title>
  <acronym>SMILE</acronym>
  <official_title>Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A premarket, international multicenter, prospective, open label, adaptive, randomized
      controlled study.

      The aim is to evaluate the efficacy of sensor augmented pump therapy with MiniMed™640G and
      SmartGuard™in preventing hypoglycemic events in comparison with continuous subcutaneous
      insulin infusion therapy in type 1 diabetes adults with an increased risk of hypoglycemia.
      The primary objective is to demonstrate a reduction in the mean number of hypoglycemic
      events when using the MiniMed™640G system with SmartGuard™ and the secondary objectives will
      aim at evaluating the difference in glycemic parameters and HbA1c.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of sensor glucose hypoglycaemic events below or equal to 55 mg/dL per patient/week.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean time spent of sensor glucose values below or equal 40 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time spent of sensor glucose values below or equal 55 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time spent of sensor glucose values below or equal 70 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of sensor glucose values below or equal 70 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of sensor glucose values below or equal 55 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean AUC of sensor glucose values below or equal 40 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time spent of sensor glucose values within range and including 70-140 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time spent of sensor glucose values within range and including 70-180 mg/dL.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean amplitude of glycaemic excursions.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean HbA1c change from baseline to 6 months.</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Severe Hypoglycemic Events</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number Diabetic Ketoacidosis Events</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number Serious Adverse Events</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number Device Deficiencies</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number Serious Adverse Device Effects</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Diabetes Treatment Satisfaction Questionnaire score.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Hypoglycemia Fear Survey score.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Gold Questionnaire score.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Clarke Questionnaire score</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number hypoglycemia-related days missed from school or work.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number hypoglycemia-related of emergency room admissions.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number hypoglycemia-related hospitalizations.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number hypoglycemia-related intensive care unit care admissions.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number hypoglycemia-related ambulance assistance events.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean insulin total daily delivery dose</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean weight</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MiniMed™640G and Suspend before Low feature of SmartGuard™ turned on.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MiniMed™640G alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiniMed™640G and Suspend before low</intervention_name>
    <description>All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.
Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>MiniMed™640G and SmartGuard™</other_name>
    <other_name>MiniMed™640G and Predictive Low Glucose Management</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MiniMed™640G</intervention_name>
    <description>Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 24-75 years old at time of screening.

          -  Diagnosed with Type 1 diabetes ≥10 years prior to screening.

          -  On pump therapy for ≥ 6 months prior to screening.

          -  Not on Real Time continuous glucose monitoring for ≥ 3 months prior to screening.

          -  HbA1c value ≥5.8% and ≤10.0% as assessed by local lab ≤ 15 days prior to screening or
             performed at screening.

          -  A documented Severe Hypoglycemia event ≤ 12 months prior to screening, OR Clarke
             score ≥4 assessed at time of screening, OR

          -  Gold score ≥4 assessed at time of screening.

          -  Subject is willing to sign and date informed consent, comply with all study
             procedures and wear all study devices as required during the study.

        Exclusion Criteria:

          -  Untreated Addison's disease, thyroid disorder, growth hormone deficiency,
             hypopituitarism or definite gastroparesis, per investigator judgment.

          -  Subject is using Pramlintide (Symlin) SGLT2 inhibitor, GLP agonist at time of
             screening.

          -  Renal failure defined by creatinine clearance &lt;30 ml/min, as assessed by local lab
             test ≤ 3 months before screening or performed at screening at local lab.

          -  Hearing or vision impairment hindering perception of glucose display and alarms, or
             otherwise incapable of using the study devices, per investigator judgment.

          -  Current pregnancy or intention to conceive.

          -  Any unresolved adverse skin condition in the area of sensor placement (e.g.
             psoriasis, rash, Staphylococcus infection).

          -  Alcohol or drug abuse, other than nicotine, per investigator judgment.

          -  Any other disease or condition that may preclude the patient from participating in
             the study, per investigator judgment.

          -  Legally incompetent, illiterate or vulnerable person.

        Randomization Criteria:

          -  If subjects meet the above criteria, as well as all of the following criteria
             assessed at the end of the run-in period, they may continue to participate in the
             treatment period of the study:

               -  Subject has worn two weeks the sensor with transmitter during the run-in period.

               -  Subject has shown acceptable tolerance of sensor wear, per investigator
                  judgment.

               -  Subject performed ≥ 4 finger stick blood glucose measurements daily, as
                  determined by CareLink™ Clinical data upload as the mean number of SMBG/day over
                  the past 14 days (SMBG number / day ≥ 3.5 rounds up to 4).

               -  Subject showed ability to comprehend the pump training and study procedures, per
                  investigator judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linda Vorrink - de Groot, MSc</last_name>
    <phone>+41218038084</phone>
    <email>linda.vorrink@medtronic.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Da Silva, MSc</last_name>
    <phone>+41218038533</phone>
    <email>julien.da.silva@medtronic.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sophie Borot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sandrine Lablanche</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM - La Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pauline Schaepelynck-Belicar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Wojtusciszyn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Roberto Trevisan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emanuele Bosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Laurenzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Gionanni di Dio</name>
      <address>
        <city>Olbia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Giancarlo Tonolo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groene Hart Ziekenhuis</name>
      <address>
        <city>Gouda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roel Hoogma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joke van der Linden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Silvius</last_name>
    </contact>
    <investigator>
      <last_name>Harold de Valk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Titia Vriesendorp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harrogate District Hospital</name>
      <address>
        <city>Harrogate</city>
        <state>N. Yorkshire</state>
        <zip>HG2 7SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Carling</last_name>
      <phone>01423 555345</phone>
      <email>JANET.CARLING@hdft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Peter Hammond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <zip>SE5 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geraldine Gallen</last_name>
      <email>geraldinegallen@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Pratik Choudhary, MBBS, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Diabetes Center</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lalantha Leelarathna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle Upon Tyne Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Stuart Little</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 3, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
